Eli Lilly’s Weight-Loss Drug Strategy Reveals What Institutional Priorities Actually Are When Patient Access Remains an Option
Eli Lilly announced this week that it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in the first quarter of 2027. The company is deliberately pursuing biologic drug classification—not because it’s medically superior, but because it extends patent protection and prevents generic competition for 15-20 years. This is a strategic choice about how…
